ClinicalTrials.gg
RecruitingNCT07458347Updated Nov 20, 2026

A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

A Phase 1 interventional study of KST-6051 and Gemcitabine/nab-paclitaxel in KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) and KRAS-mutant Colorectal Cancer (CRC), sponsored by Kestrel Therapeutics, Inc.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Kestrel Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know · 19 judgments

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 15, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
545
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.

Planned enrollment
134th of 1,908
545 · median 48
Started
2026
with 111 others
Phase 1
448 of 2,462
58 open now
Primary completion
2028-04
later than 440 of 638 live
Registered
2,392nd of 2,462
by date

Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 134th largest by planned enrollment of the 1,908 interventional ones that give a count, is one of 112 that started in 2026, is one of 448 in phase 1, reaches primary completion later than 440 of the 638 other live ones, and was the 2,392nd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

418 more — sign in →

All 423 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,462 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.

Read the detailed description

This is a first-in-human, phase 1, open-label, multicenter clinical trial designed to evaluate safety, tolerability, pharmacokinetics, biomarkers, pharmacodynamics and preliminary activity of orally administered KST-6051 as monotherapy or in combination with other anticancer agents. The trial seeks to enroll adults with advanced or metastatic KRAS mutant solid tumors including but not limited to pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer whose cancers have progressed after prior therapy or in whom standard therapy was not tolerated. The trial includes a dose escalation phase in which higher doses of KST-6051 will be given in subsequent groups of participants. The trial also includes a dose expansion phase to further investigate KST-6051. Participants can stay in the trial as long as they benefit from the treatment and can tolerate it.

03

Conditions studied

  • KRAS-mutant Non-small Cell Lung Cancer (NSCLC)
  • KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
  • KRAS-mutant Colorectal Cancer (CRC)
  • Other KRAS-mutant Solid Tumors

Keywords

  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • KRAS Mutation
  • KST-6051
  • KRAS
  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Colon Cancer
  • Rectal Cancer
  • Endometrial Cancer
  • Cholangiocarcinoma
  • Metastatic Cancer
  • Pan KRAS
  • Biliary Tract Cancer
  • Post-RAS targeted therapies
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Willing and able to give written .
  3. documented locally advanced and unresectable or NSCLC, PDAC, CRC, or other solid tumor.
  4. Documentation of KRAS mutation prior to the first dose of trial drug(s).
  5. Performance Status (ECOG PS) of 0 or 1.
  6. Adequate cardiovascular, hematological, liver, and renal function.
  7. at baseline per version 1.1 (RECIST 1.1).

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system (CNS) tumors or untreated or unstable .
  2. Inability to swallow oral medications.
  3. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial.

Other inclusion/exclusion criteria are specified in the protocol.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
545 participants (estimated)

Study arms

  • Experimental
    KST-6051 Dose Escalation Monotherapy

    Sequential cohorts with increasing doses of KST-6051 as monotherapy will be evaluated to determine recommended dose(s) for expansion (RDE\[s\]).

    Drug: KST-6051

  • Experimental
    KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel

    Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of gemcitabine/nab-paclitaxel will be evaluated in participants with previously treated PDAC.

    Drug: KST-6051 · Drug: Gemcitabine/nab-paclitaxel

  • Experimental
    KST-6051 Dose Escalation Combination Therapy with Cetuximab

    Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of cetuximab will be evaluated in participants with previously treated KRAS-mutant mCRC.

    Drug: KST-6051 · Drug: Cetuximab

  • Experimental
    KST-6051 Dose Escalation Combination Therapy with Pembrolizumab

    Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of pembrolizumab will be evaluated in participants with first- or second-line KRAS-mutant NSCLC.

    Drug: KST-6051 · Drug: Pembrolizumab

  • Experimental
    KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in PDAC after 1 or 2 prior lines of therapy.

    Drug: KST-6051

  • Experimental
    KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in mCRC after 1 or 2 prior lines of therapy.

    Drug: KST-6051

  • Experimental
    KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in NSCLC after 1 or 2 prior lines of therapy.

    Drug: KST-6051

  • Experimental
    KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in prior RAS/KRAS inhibitor-treated solid tumors.

    Drug: KST-6051

  • Experimental
    KST-6051 Dose Expansion Monotherapy in Later-line Settings

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in selected KRAS-mutant biliary tract cancer, endometrial cancer (EC), or other solid tumors in later-line settings.

    Drug: KST-6051

  • Experimental
    KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with gemcitabine/nab-paclitaxel in 1L PDAC.

    Drug: KST-6051 · Drug: Gemcitabine/nab-paclitaxel

  • Experimental
    KST-6051 Dose Expansion Combination Therapy with Cetuximab

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with cetuximab in 2L/3L CRC.

    Drug: KST-6051 · Drug: Cetuximab

  • Experimental
    KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with cetuximab and mFOLFOX6 or FOLFIRI in 1L CRC.

    Drug: KST-6051 · Drug: Cetuximab · Drug: mFOLFOX6 · Drug: FOLFIRI

  • Experimental
    KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin

    Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with pembrolizumab and pemetrexed/carboplatin in 1L NSCLC.

    Drug: KST-6051 · Drug: Pembrolizumab · Drug: Pemetrexed · Drug: Carboplatin

Interventions

  • DrugKST-6051

    KST-6051 will be administered orally as a tablet.

  • DrugGemcitabine/nab-paclitaxel

    Gemcitabine/nab-paclitaxel will be administered intravenously (IV).

  • Cetuximab will be administered IV.

  • Pembrolizumab will be administered IV.

  • DrugmFOLFOX6

    mFOLFOX6 will be administered IV.

  • DrugFOLFIRI

    FOLFIRI will be administered IV.

  • Pemetrexed will be administered IV.

  • Carboplatin will be administered IV.

06

What researchers measure

Primary outcomes

  1. Dose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days)

    Time frame: Up to Day 21 of Treatment Cycle 1

  2. Dose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Clinically significant changes in safety assessments (vital signs, physical examinations, electrocardiograms, and clinical laboratory tests) are to be reported as adverse events.

    Time frame: Up to approximately 2 years

  3. Dose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs)

    Clinically significant changes in safety assessments (vital signs, physical examinations, electrocardiograms, and clinical laboratory tests) are to be reported as adverse events.

    Time frame: Up to approximately 2 years

  4. Dose Expansion Cohorts: Confirmed Objective Response Rate (ORR)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Dose Escalation Cohorts: Maximum Observed Blood Concentration (Cmax) of KST-6051 Alone

    Time frame: Up to Week 6

  2. Dose Escalation Cohorts: Cmax of KST-6051 in Combination with Other Agents

    Time frame: Up to Week 6

  3. Dose Escalation Cohorts: Time to Achieve Cmax (Tmax) of KST-6051 Alone

    Time frame: Up to Week 6

  4. Dose Escalation Cohorts: Tmax of KST-6051 in Combination with Other Agents

    Time frame: Up to Week 6

  5. Dose Escalation Cohorts: Half-life (t1/2) of KST-6051 Alone

    Time frame: Up to Week 6

  6. Dose Escalation Cohorts: t1/2 of KST-6051 in Combination with Other Agents

    Time frame: Up to Week 6

  7. Dose Escalation Cohorts: Area Under the Blood Concentration-time Curve (AUC) of KST-6051 Alone

    Time frame: Up to Week 6

  8. Dose Escalation Cohorts: AUC of KST-6051 in Combination with Other Agents

    Time frame: Up to Week 6

  9. Dose Escalation Cohorts: ORR

    Time frame: Up to approximately 2 years

  10. Dose Escalation and Dose Expansion Cohorts: Disease Control Rate (DCR)

    Time frame: Up to approximately 2 years

  11. Dose Escalation and Dose Expansion Cohorts: Duration of Overall Response (DOR)

    Time frame: Up to approximately 2 years

  12. Dose Escalation and Dose Expansion Cohorts: Progression-free Survival (PFS)

    Time frame: Up to approximately 2 years

  13. Dose Escalation and Dose Expansion Cohorts: Overall Survival (OS)

    Time frame: Up to approximately 2 years

  14. Dose Escalation Cohorts: Duration of Stable Disease

    Time frame: Up to approximately 2 years

  15. Dose Expansion Cohorts: Time to Response (TTR)

    Time frame: Up to approximately 2 years

  16. Dose Expansion Cohorts: Number of Participants With TEAEs

    Time frame: Up to approximately 2 years

  17. Dose Expansion Cohorts: Number of Participants with Dose Interruptions, Dose Reductions, and Discontinuations

    Time frame: Up to approximately 2 years

  18. Dose Expansion Cohorts: Relative Dose Intensity and Treatment Exposure

    Time frame: Up to approximately 2 years

  19. Dose Expansion Cohorts: Concentration of KST-6051 in the Whole Blood After Multiple Dose Administration

    Time frame: Up to Week 6

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 164 non-industry phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 90. This study's planned 24 months is below that.

Counting every sponsor, half of 294 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jun 2027 → Apr 2028 and completion May 2028 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 9, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Apr 2028was Jun 2027
CompletionEst.
Apr 2029was May 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2027→Apr 2028
Oct 15, 2026
Study completion
May 2028→Apr 2029
Oct 15, 2026
Enrollment
145→545
Oct 15, 2026
Eligibility
1 inclusion criterion removed; 1 exclusion criterion edited, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedProgressed on or intolerant to standard treatment(s).
Exclusion criteria
  • RemovedPrevious or current treatment with RAS or KRAS inhibitors.
  • EditedCentral nervous system (CNS) tumors or untreated or unstable metastases.
Oct 15, 2026
Interventions
Added Drug: Gemcitabine/nab-paclitaxel·Drug: Cetuximab·Drug: Pembrolizumab·Drug: mFOLFOX6·Drug: FOLFIRI·and 2 more
All 7

Drug: Gemcitabine/nab-paclitaxel · Drug: Cetuximab · Drug: Pembrolizumab · Drug: mFOLFOX6 · Drug: FOLFIRI · Drug: Pemetrexed · Drug: Carboplatin

. Arm changed KST-6051 Dose Escalation→KST-6051 Dose Escalation Monotherapy. Arms added: KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel·KST-6051 Dose Escalation Combination Therapy with Cetuximab·KST-6051 Dose Escalation Combination Therapy with Pembrolizumab·KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy·KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy·and 7 more
All 12

KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel · KST-6051 Dose Escalation Combination Therapy with Cetuximab · KST-6051 Dose Escalation Combination Therapy with Pembrolizumab · KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors · KST-6051 Dose Expansion Monotherapy in Later-line Settings · KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel · KST-6051 Dose Expansion Combination Therapy with Cetuximab · KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI · KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin

Oct 15, 2026
Primary outcomes
3 edited, 1 added
What changed in the outcomes
  • EditedDose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days)Time frame: Up to Day 21 of Treatment Cycle 1
  • EditedDose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2 years
  • EditedDose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs)Time frame: Up to approximately 2 years
  • AddedDose Expansion Cohorts: Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 2 years
Oct 15, 2026
Secondary outcomes
8 edited, 11 added, 1 removed
What changed in the outcomes
  • EditedDose Escalation Cohorts: Maximum Observed Blood Concentration (Cmax) of KST-6051 AloneTime frame: Up to Week 6
  • EditedDose Escalation Cohorts: Time to Achieve Cmax (Tmax) of KST-6051 AloneTime frame: Up to Week 6
  • EditedDose Escalation Cohorts: Half-life (t1/2) of KST-6051 AloneTime frame: Up to Week 6
  • EditedDose Escalation Cohorts: Area Under the Blood Concentration-time Curve (AUC) of KST-6051 AloneTime frame: Up to Week 6
  • EditedDose Escalation and Dose Expansion Cohorts: Disease Control Rate (DCR)Time frame: Up to approximately 2 years
  • EditedDose Escalation and Dose Expansion Cohorts: Duration of Overall Response (DOR)Time frame: Up to approximately 2 years
  • EditedDose Escalation and Dose Expansion Cohorts: Progression-free Survival (PFS)Time frame: Up to approximately 2 years
  • EditedDose Escalation Cohorts: Duration of Stable DiseaseTime frame: Up to approximately 2 years
  • AddedDose Escalation Cohorts: Cmax of KST-6051 in Combination with Other AgentsTime frame: Up to Week 6
  • AddedDose Escalation Cohorts: Tmax of KST-6051 in Combination with Other AgentsTime frame: Up to Week 6
  • AddedDose Escalation Cohorts: t1/2 of KST-6051 in Combination with Other AgentsTime frame: Up to Week 6
  • AddedDose Escalation Cohorts: AUC of KST-6051 in Combination with Other AgentsTime frame: Up to Week 6
  • AddedDose Escalation Cohorts: ORRTime frame: Up to approximately 2 years
  • AddedDose Escalation and Dose Expansion Cohorts: Overall Survival (OS)Time frame: Up to approximately 2 years
  • AddedDose Expansion Cohorts: Time to Response (TTR)Time frame: Up to approximately 2 years
  • AddedDose Expansion Cohorts: Number of Participants With TEAEsTime frame: Up to approximately 2 years
  • AddedDose Expansion Cohorts: Number of Participants with Dose Interruptions, Dose Reductions, and DiscontinuationsTime frame: Up to approximately 2 years
  • AddedDose Expansion Cohorts: Relative Dose Intensity and Treatment ExposureTime frame: Up to approximately 2 years
  • AddedDose Expansion Cohorts: Concentration of KST-6051 in the Whole Blood After Multiple Dose AdministrationTime frame: Up to Week 6
  • RemovedObjective Response Rate (ORR)Time frame: Up to approximately 2 years
Oct 15, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Sidney Kimmel Cancer Center · Philadelphia, United StatesContact added A•••@jefferson.edu
  • The University of Texas MD Anderson Cancer Center · Houston, United StatesContact added d•••@mdanderson.org
  • Huntsman Cancer Institute, University of Utah · Salt Lake City, United StatesContact added s•••@hci.utah.edu · •••3453
  • NEXT Virginia · Fairfax, United StatesContact added c•••@usoncology.com · •••1473
  • Moffitt Cancer Center · Tampa, United StatesContact added k•••@moffitt.org · •••5804
across 2 updates, Nov 12, 2026 – Nov 20, 2026
Title
A Phase 1 Dose-escalation Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Oct 15, 2026
Show all 3 updates
  1. Nov 20, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Moffitt Cancer Center · Tampa, United StatesContact added k•••@moffitt.org · •••5804
  2. Nov 12, 2026
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Sidney Kimmel Cancer Center · Philadelphia, United StatesContact added A•••@jefferson.edu
    • The University of Texas MD Anderson Cancer Center · Houston, United StatesContact added d•••@mdanderson.org
    • Huntsman Cancer Institute, University of Utah · Salt Lake City, United StatesContact added s•••@hci.utah.edu · •••3453
    • NEXT Virginia · Fairfax, United StatesContact added c•••@usoncology.com · •••1473
  3. Oct 15, 2026
    Primary completion Jun 2027→Apr 2028
    Study completion May 2028→Apr 2029
    Enrollment 145→545
    Eligibility 1 inclusion criterion removed; 1 exclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedProgressed on or intolerant to standard treatment(s).
    Exclusion criteria
    • RemovedPrevious or current treatment with RAS or KRAS inhibitors.
    • EditedCentral nervous system (CNS) tumors or untreated or unstable metastases.
    Primary outcomes 3 edited, 1 added
    What changed in the outcomes
    • EditedDose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days)Time frame: Up to Day 21 of Treatment Cycle 1
    • EditedDose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2 years
    • EditedDose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs)Time frame: Up to approximately 2 years
    • AddedDose Expansion Cohorts: Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 2 years
    Secondary outcomes 8 edited, 11 added, 1 removed
    What changed in the outcomes
    • EditedDose Escalation Cohorts: Maximum Observed Blood Concentration (Cmax) of KST-6051 AloneTime frame: Up to Week 6
    • EditedDose Escalation Cohorts: Time to Achieve Cmax (Tmax) of KST-6051 AloneTime frame: Up to Week 6
    • EditedDose Escalation Cohorts: Half-life (t1/2) of KST-6051 AloneTime frame: Up to Week 6
    • EditedDose Escalation Cohorts: Area Under the Blood Concentration-time Curve (AUC) of KST-6051 AloneTime frame: Up to Week 6
    • EditedDose Escalation and Dose Expansion Cohorts: Disease Control Rate (DCR)Time frame: Up to approximately 2 years
    • EditedDose Escalation and Dose Expansion Cohorts: Duration of Overall Response (DOR)Time frame: Up to approximately 2 years
    • EditedDose Escalation and Dose Expansion Cohorts: Progression-free Survival (PFS)Time frame: Up to approximately 2 years
    • EditedDose Escalation Cohorts: Duration of Stable DiseaseTime frame: Up to approximately 2 years
    • AddedDose Escalation Cohorts: Cmax of KST-6051 in Combination with Other AgentsTime frame: Up to Week 6
    • AddedDose Escalation Cohorts: Tmax of KST-6051 in Combination with Other AgentsTime frame: Up to Week 6
    • AddedDose Escalation Cohorts: t1/2 of KST-6051 in Combination with Other AgentsTime frame: Up to Week 6
    • AddedDose Escalation Cohorts: AUC of KST-6051 in Combination with Other AgentsTime frame: Up to Week 6
    • AddedDose Escalation Cohorts: ORRTime frame: Up to approximately 2 years
    • AddedDose Escalation and Dose Expansion Cohorts: Overall Survival (OS)Time frame: Up to approximately 2 years
    • AddedDose Expansion Cohorts: Time to Response (TTR)Time frame: Up to approximately 2 years
    • AddedDose Expansion Cohorts: Number of Participants With TEAEsTime frame: Up to approximately 2 years
    • AddedDose Expansion Cohorts: Number of Participants with Dose Interruptions, Dose Reductions, and DiscontinuationsTime frame: Up to approximately 2 years
    • AddedDose Expansion Cohorts: Relative Dose Intensity and Treatment ExposureTime frame: Up to approximately 2 years
    • AddedDose Expansion Cohorts: Concentration of KST-6051 in the Whole Blood After Multiple Dose AdministrationTime frame: Up to Week 6
    • RemovedObjective Response Rate (ORR)Time frame: Up to approximately 2 years
    Interventions Added Drug: Gemcitabine/nab-paclitaxel·Drug: Cetuximab·Drug: Pembrolizumab·Drug: mFOLFOX6·Drug: FOLFIRI·and 2 more
    All 7

    Drug: Gemcitabine/nab-paclitaxel · Drug: Cetuximab · Drug: Pembrolizumab · Drug: mFOLFOX6 · Drug: FOLFIRI · Drug: Pemetrexed · Drug: Carboplatin

    . Arm changed KST-6051 Dose Escalation→KST-6051 Dose Escalation Monotherapy. Arms added: KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel·KST-6051 Dose Escalation Combination Therapy with Cetuximab·KST-6051 Dose Escalation Combination Therapy with Pembrolizumab·KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy·KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy·and 7 more
    All 12

    KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel · KST-6051 Dose Escalation Combination Therapy with Cetuximab · KST-6051 Dose Escalation Combination Therapy with Pembrolizumab · KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors · KST-6051 Dose Expansion Monotherapy in Later-line Settings · KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel · KST-6051 Dose Expansion Combination Therapy with Cetuximab · KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI · KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin

    Title A Phase 1 Dose-escalation Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
    + 5 other changes: index terms, verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07458347
Lead sponsor
Kestrel Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Apr 21, 2026
Primary completion
Apr 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Kestrel Therapeutics, Inc.
Contact
clinicaltrials@kestreltherapeutics.com
617-612-6810

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion